The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
PXS-5505: Investigational New Drug application has been submitted to the FDA
Following the recent U.S. Food and Drug Administration (FDA) orphan drug designation, an Investigational New Drug (IND) application has been submitted for a phase I/II study of PXS-5505, a pan-lysyl oxidase (LOX) inhibitor, which is currently under development for the treatment of myelofibrosis.
PXS-5505 has been previously tested in healthy volunteers in a phase I study. The IND submission protocol covers a dose escalation study for 1 month, and an open-label, 6-month treatment phase in patients who are not receiving a Janus kinase inhibitor. The study is planned to be started by the end of 2020 and be completed in 2022.
Inhibition of LOX family members is expected to show benefits of reduced fibrotic burden and to have favorable effects on aberrant blood cell production seen in myelofibrosis.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content